innoVitro GmbH is a preclinical contract research organization providing human cardiac risk and efficacy testing services to pharmaceutical, biotech and academic companies worldwide. Each service is customized by a team of experts in close collaboration with the client and delivered as an end-to-end study report in less than 6 weeks. Screening parameters include structural and functional endpoints of human iPSC-derived cardiomyocytes analyzed using a high-throughput 96-well hybrid system. innovitro.de